<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857623</url>
  </required_header>
  <id_info>
    <org_study_id>D0475C00009</org_study_id>
    <nct_id>NCT00857623</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy</brief_title>
  <official_title>A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if AZD2066 can relieve the pain arising from
      painful diabetic neuropathy compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment</measure>
    <time_frame>From baseline to day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of mean pain intensity from 5-day baseline to the last 5 days of treatment, measured twice daily with NRS (12 hours recall).
Mean pain intensity for 5-day baseline period (evening Day -6 to moning Day-1) and mean pain intensity for last 5 days on treatment (ie, last dose day and the 4 preceding calendar days) was calculated based on the numerical rating scale (NRS)(0-10). 0=No pain, 10=Worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Numerical Rating Scale (NRS) Pain Scores and Change From Baseline Over Time to Day 28.</measure>
    <time_frame>From baseline to 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean pain intensity per day (mean of morning and evening NRS values) and change from baseline were calculated for each study day. Baseline value= mean pain intensity for the 5-day baseline period. NRS scale (0- 10) where 0= No pain and 10= Worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With &gt;=30% Reduction From Baseline in Numerical Rating Scale (NRS) Pain Intensity Score at Day 28</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain intensity score reduction=(change from baseline at D28/baseline)*100 Responder= pain intensity score reduction ≥30% (yes/no)? Responder rate= (no. of responders/total no. of patients)*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With &gt;=50% Reduction From Baseline in Numerical Rating Scale (NRS) Pain Intensity Score at Day 28</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain intensity score reduction= (change from baseline D28/baseline)*100 Responder=pain intensity score reduction ≥50% (Yes/No)? Responder rate= (no. of responders/total no. of patients)*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Patient Global Impression of Change (PGIC) Score of at Least &quot;Much Improved&quot; at Day 28.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient Global Impression of Change (PGIC) scale ranges from 1-7, where 1= Very much improved and 7= Very much worse.
Responder= Patient with a response of &quot;much improved&quot; or &quot;very much improved&quot; Responder rate= (no. of responders/total no. of patients)*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in McGill Pain Questionnaire Short Form (MPQ-SF) Sensory Index From Baseline to Day 28.</measure>
    <time_frame>From baseline to day 28.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensory index= sum of the intensity scale values of the words chosen for the descriptors 1-11 in the questionnaire. Range of scores for the sensory index= 0-33 (higher score represents a worse condition).
Change from baseline (measured prior to randomization) to Day 28 was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in McGill Pain Questionnaire Short Form (MPQ-SF) Affective Index From Baseline to Day 28.</measure>
    <time_frame>From baseline to day 28.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Affective index= sum of the intensity scale values of the words chosen for the descriptors 12-15 in the questionnaire. Range of scores for the affective index=0-12 (higher score represents a worse condition).
Change from baseline (measured prior to randomization) to Day 28 was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Severity From Baseline to Day 28.</measure>
    <time_frame>From baseline to day 28..</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (measured prior to randomization) to Day 28 was calculated for the pain severity (mean of 4 intensity items). Each intensity item is recorded on a Numerical rating Scale (NRS) 0-10, where 0=No pain and 10= The worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Interference From Baseline to Day 28.</measure>
    <time_frame>From baseline to 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (measured prior to randomization) to Day 28 was calculated for pain interference (mean of 7 interference items). Each interference item is recorded on a Numerical Rating Scale (NRS 0-10), where 0= No interference and 10= Interferes completely.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Pain</condition>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2066</intervention_name>
    <description>Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures.

          -  Clinical diagnosis of painful diabetic neuropathy.

          -  non-fertile females

        Exclusion Criteria:

          -  Other pain that may confound assessment of neuropathic pain.

          -  Ongoing significant peripheral arterial diseases, skin ulcers, or amputation in the
             lower extremities.

          -  History of psychotic disorders among first degree relatives.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biljana Lilja</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Södertälje151 85 Södertälje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles E Argoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical , NY 12208, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reserach Site</name>
      <address>
        <city>Bella Vista</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Owing Mills</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reasearch Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 8, 2012</lastchanged_date>
  <firstreceived_date>February 27, 2009</firstreceived_date>
  <firstreceived_results_date>September 28, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Diabetic Neuropathy</keyword>
  <keyword>PDN</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Efficacy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multicenter study was conducted between February 2009 and August 2009in the United States.</recruitment_details>
      <pre_assignment_details>The study consisted of a 42-day enrollment phase (including washout and baseline period), a 28-day treatment phase (10-day inpatient and 18-day outpatient) where patients were randomized to AZD2066 or placebo, and a 7-day follow-up phase. Patients randomized to treatment with AZD2066 received 12 mg from Days 1 to 4 and 18 mg from Days 5 to 28.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD2066</title>
          <description>Capsule, once daily. 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Capsule, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intake of prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive for HEP C</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD2066</title>
          <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Capsule, once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="65"/>
                <measurement group_id="B3" value="127"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>All randomized patients.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="59.2" spread="9.2"/>
                <measurement group_id="B2" value="57.0" spread="8.7"/>
                <measurement group_id="B3" value="58.1" spread="8.95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>All randomized patients.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment</title>
        <description>Change of mean pain intensity from 5-day baseline to the last 5 days of treatment, measured twice daily with NRS (12 hours recall).
Mean pain intensity for 5-day baseline period (evening Day -6 to moning Day-1) and mean pain intensity for last 5 days on treatment (ie, last dose day and the 4 preceding calendar days) was calculated based on the numerical rating scale (NRS)(0-10). 0=No pain, 10=Worst pain imaginable.</description>
        <time_frame>From baseline to day 28</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment</title>
            <description>Change of mean pain intensity from 5-day baseline to the last 5 days of treatment, measured twice daily with NRS (12 hours recall).
Mean pain intensity for 5-day baseline period (evening Day -6 to moning Day-1) and mean pain intensity for last 5 days on treatment (ie, last dose day and the 4 preceding calendar days) was calculated based on the numerical rating scale (NRS)(0-10). 0=No pain, 10=Worst pain imaginable.</description>
            <units>Scores on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-2.33" spread="0.37"/>
                  <measurement group_id="O2" value="-2.52" spread="0.36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Numerical Rating Scale (NRS) Pain Scores and Change From Baseline Over Time to Day 28.</title>
        <description>Mean pain intensity per day (mean of morning and evening NRS values) and change from baseline were calculated for each study day. Baseline value= mean pain intensity for the 5-day baseline period. NRS scale (0- 10) where 0= No pain and 10= Worst pain imaginable.</description>
        <time_frame>From baseline to 28 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Daily Numerical Rating Scale (NRS) Pain Scores and Change From Baseline Over Time to Day 28.</title>
            <description>Mean pain intensity per day (mean of morning and evening NRS values) and change from baseline were calculated for each study day. Baseline value= mean pain intensity for the 5-day baseline period. NRS scale (0- 10) where 0= No pain and 10= Worst pain imaginable.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-2.3" spread="2.2"/>
                  <measurement group_id="O2" value="-2.5" spread="2.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With &gt;=30% Reduction From Baseline in Numerical Rating Scale (NRS) Pain Intensity Score at Day 28</title>
        <description>Pain intensity score reduction=(change from baseline at D28/baseline)*100 Responder= pain intensity score reduction ≥30% (yes/no)? Responder rate= (no. of responders/total no. of patients)*100</description>
        <time_frame>28 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With &gt;=30% Reduction From Baseline in Numerical Rating Scale (NRS) Pain Intensity Score at Day 28</title>
            <description>Pain intensity score reduction=(change from baseline at D28/baseline)*100 Responder= pain intensity score reduction ≥30% (yes/no)? Responder rate= (no. of responders/total no. of patients)*100</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With &gt;=50% Reduction From Baseline in Numerical Rating Scale (NRS) Pain Intensity Score at Day 28</title>
        <description>Pain intensity score reduction= (change from baseline D28/baseline)*100 Responder=pain intensity score reduction ≥50% (Yes/No)? Responder rate= (no. of responders/total no. of patients)*100</description>
        <time_frame>28 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With &gt;=50% Reduction From Baseline in Numerical Rating Scale (NRS) Pain Intensity Score at Day 28</title>
            <description>Pain intensity score reduction= (change from baseline D28/baseline)*100 Responder=pain intensity score reduction ≥50% (Yes/No)? Responder rate= (no. of responders/total no. of patients)*100</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Patient Global Impression of Change (PGIC) Score of at Least “Much Improved” at Day 28.</title>
        <description>Patient Global Impression of Change (PGIC) scale ranges from 1-7, where 1= Very much improved and 7= Very much worse.
Responder= Patient with a response of &quot;much improved&quot; or &quot;very much improved&quot; Responder rate= (no. of responders/total no. of patients)*100</description>
        <time_frame>28 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With Patient Global Impression of Change (PGIC) Score of at Least “Much Improved” at Day 28.</title>
            <description>Patient Global Impression of Change (PGIC) scale ranges from 1-7, where 1= Very much improved and 7= Very much worse.
Responder= Patient with a response of &quot;much improved&quot; or &quot;very much improved&quot; Responder rate= (no. of responders/total no. of patients)*100</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in McGill Pain Questionnaire Short Form (MPQ-SF) Sensory Index From Baseline to Day 28.</title>
        <description>Sensory index= sum of the intensity scale values of the words chosen for the descriptors 1-11 in the questionnaire. Range of scores for the sensory index= 0-33 (higher score represents a worse condition).
Change from baseline (measured prior to randomization) to Day 28 was calculated.</description>
        <time_frame>From baseline to day 28.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in McGill Pain Questionnaire Short Form (MPQ-SF) Sensory Index From Baseline to Day 28.</title>
            <description>Sensory index= sum of the intensity scale values of the words chosen for the descriptors 1-11 in the questionnaire. Range of scores for the sensory index= 0-33 (higher score represents a worse condition).
Change from baseline (measured prior to randomization) to Day 28 was calculated.</description>
            <units>Scores on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-6.87" spread="0.93"/>
                  <measurement group_id="O2" value="-7.68" spread="0.88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in McGill Pain Questionnaire Short Form (MPQ-SF) Affective Index From Baseline to Day 28.</title>
        <description>Affective index= sum of the intensity scale values of the words chosen for the descriptors 12-15 in the questionnaire. Range of scores for the affective index=0-12 (higher score represents a worse condition).
Change from baseline (measured prior to randomization) to Day 28 was calculated.</description>
        <time_frame>From baseline to day 28.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in McGill Pain Questionnaire Short Form (MPQ-SF) Affective Index From Baseline to Day 28.</title>
            <description>Affective index= sum of the intensity scale values of the words chosen for the descriptors 12-15 in the questionnaire. Range of scores for the affective index=0-12 (higher score represents a worse condition).
Change from baseline (measured prior to randomization) to Day 28 was calculated.</description>
            <units>Scores on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.87" spread="0.35"/>
                  <measurement group_id="O2" value="-2.06" spread="0.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Severity From Baseline to Day 28.</title>
        <description>Change from baseline (measured prior to randomization) to Day 28 was calculated for the pain severity (mean of 4 intensity items). Each intensity item is recorded on a Numerical rating Scale (NRS) 0-10, where 0=No pain and 10= The worst pain.</description>
        <time_frame>From baseline to day 28..</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Severity From Baseline to Day 28.</title>
            <description>Change from baseline (measured prior to randomization) to Day 28 was calculated for the pain severity (mean of 4 intensity items). Each intensity item is recorded on a Numerical rating Scale (NRS) 0-10, where 0=No pain and 10= The worst pain.</description>
            <units>Scores on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.99" spread="0.35"/>
                  <measurement group_id="O2" value="-2.19" spread="0.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Interference From Baseline to Day 28.</title>
        <description>Change from baseline (measured prior to randomization) to Day 28 was calculated for pain interference (mean of 7 interference items). Each interference item is recorded on a Numerical Rating Scale (NRS 0-10), where 0= No interference and 10= Interferes completely.</description>
        <time_frame>From baseline to 28 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol population (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2066</title>
            <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Capsule, once daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Interference From Baseline to Day 28.</title>
            <description>Change from baseline (measured prior to randomization) to Day 28 was calculated for pain interference (mean of 7 interference items). Each interference item is recorded on a Numerical Rating Scale (NRS 0-10), where 0= No interference and 10= Interferes completely.</description>
            <units>Scores on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-2.13" spread="0.31"/>
                  <measurement group_id="O2" value="-2.13" spread="0.30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD2066</title>
          <description>Capsule, once daily 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Capsule, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive; Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
